BSE filing, NSE: TRABI. Summary written from the filing by ALFA Finder's alert engine.
Transgene Biotek Ltd: key numbers
- Share price
- ₹2.33
- Market cap
- ₹17.65 Cr
- Revenue (annual)
- ₹0.21 Cr
- Net profit (annual)
- ₹-1.65 Cr
- P/E (TTM)
- -11.0×Sector 52.8×
- Promoter holding
- 23.64%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Transgene Biotek Ltd
All →Transgene Biotek Management Change
Transgene Biotek's statutory auditors Eswara Rao & Co. resigned effective 28 October 2026 citing pre-occupation. The company will appoint new auditors per applicable regulations.
Transgene Biotek Board Meeting Outcome
Transgene Biotek Limited appointed M/s. Eswara Rao & Co. as the new statutory auditor to fill a casual vacancy, subject to shareholder approval.
Transgene Biotek Other Announcement
The company filed a Regulation 74(5) certificate from its Registrar, confirming dematerialization activities for the quarter ended September 30, 2026.
Transgene Biotek Board Meeting Date
Transgene Biotek Ltd has scheduled a board meeting for October 10, 2026, to consider appointing a new statutory auditor to fill a casual vacancy.
Transgene Biotek Annual General Meeting
Transgene Biotek has received ROC approval to extend its 36th AGM deadline by three months. The meeting for FY2025-26 will now be held by December 31, 2026.
Transgene Biotek Management Change
Transgene Biotek Ltd announced the resignation of M/s Vasavi & Co. as Statutory Auditors, effective immediately. The auditors cited pre-occupation with other assignments as the reason.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.